Shen Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shen Zhao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chao You
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
1 shared publication - Guan-Hua Su
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
1 shared publication - He Wang
Department of Radiology, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University
1 shared publication - Jia-Yin Zhou
Department of Radiology, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
1 shared publication Lu-Yi Lin
Department of Radiology, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
1 shared publication- Rencheng Zheng
Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 6 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (40) , eadf0837
Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets
Intratumor heterogeneity (ITH) profoundly affects therapeutic responses and clinical outcomes. However, the widespread methods for assessing ITH based on genomic sequencing or pathological slides, which rely on limited tissue samples, may lead to inaccuracies due to potential sampling biases. Using a newly established multicenter breast cancer radio-multiomic dataset ( n = 1474) encompassing radiomic features extracted from dynamic contrast–enhanced magnetic resonance images, we formulated a noninvasive radiomics methodology to effectively investigate ITH. Imaging ITH (IITH) was associated with genomic and pathological ITH, predicting poor prognosis independently in breast cancer. Through multiomic analysis, we identified activated oncogenic pathways and metabolic dysregulation in high-IITH tumors. Integrated metabolomic and transcriptomic analyses highlighted ferroptosis as a vulnerability and potential therapeutic target of high-IITH tumors. Collectively, this work emphasizes the superiority of radiomics in capturing ITH. Furthermore, we provide insights into the biological basis of IITH and propose therapeutic targets for breast cancers with elevated IITH.
- 6 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (40) , eadf0837
Top Cited PapersOpen AccessRadiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets
Intratumor heterogeneity (ITH) profoundly affects therapeutic responses and clinical outcomes. However, the widespread methods for assessing ITH based on genomic sequencing or pathological slides, which rely on limited tissue samples, may lead to inaccuracies due to potential sampling biases. Using a newly established multicenter breast cancer radio-multiomic dataset ( n = 1474) encompassing radiomic features extracted from dynamic contrast–enhanced magnetic resonance images, we formulated a noninvasive radiomics methodology to effectively investigate ITH. Imaging ITH (IITH) was associated with genomic and pathological ITH, predicting poor prognosis independently in breast cancer. Through multiomic analysis, we identified activated oncogenic pathways and metabolic dysregulation in high-IITH tumors. Integrated metabolomic and transcriptomic analyses highlighted ferroptosis as a vulnerability and potential therapeutic target of high-IITH tumors. Collectively, this work emphasizes the superiority of radiomics in capturing ITH. Furthermore, we provide insights into the biological basis of IITH and propose therapeutic targets for breast cancers with elevated IITH.